(Q52976761)

English

Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility.

scientific article published in August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. (English)

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

reproducibility

1 reference

based on heuristic

inferred from title

author name string

Yun Gong

1

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

Michael Gilcrease

2

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

Nour Sneige

3

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

publication date

1 August 2005

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

Modern Pathology

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

18

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

8

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

1015-1021

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

describes a project that uses

fluorescence in situ hybridization

1 reference

based on heuristic

inferred from title

https://scigraph.springernature.com/pub.10.1038/modpathol.3800432

0 references

Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Emerging technologies for HER2 testing.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

The Measurement of Observer Agreement for Categorical Data

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

21 January 2018

The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular cytogenetics of primary breast cancer by CGH

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-colour brightfield in situ hybridisation on tissue sections

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of numerical alterations of chromosome 1 in cytopathological specimens of breast tumors by chromogen in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800432

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MODPATHOL.3800432

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

1 reference

Europe PubMed Central

10 May 2018

http://europepmc.org/abstract/MED/15861212

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52976761&oldid=1878936733"